Anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapy were found to improve the antitumor immune response of glioblastoma patients treated with targeted CD73. It is suggested that tyrosine metabolizing enzymes regulate adaptive immune processes in gliomas, which are mechanistically related to the remodeling of multiple metabolizing enzymes that induce the expression of programmed death ligand 140. This evidence concerns the gene NT5E and glioblastoma.